ACLAX
Price
$15.91
Change
+$0.14 (+0.89%)
Updated
Jun 2 closing price
Net Assets
5.58B
JVMCX
Price
$27.29
Change
+$0.24 (+0.89%)
Updated
Jun 2 closing price
Net Assets
22.49B
Interact to see
Advertisement

ACLAX vs JVMCX

Header iconACLAX vs JVMCX Comparison
Open Charts ACLAX vs JVMCXBanner chart's image
ACLAX vs JVMCX Comparison Chart in %
View a ticker or compare two or three
VS
ACLAX vs. JVMCX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLAX is a Hold and JVMCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMCX has more cash in the bank: 22.5B vs. ACLAX (5.58B). ACLAX pays higher dividends than JVMCX: ACLAX (1.11) vs JVMCX (0.00). ACLAX was incepted earlier than JVMCX: ACLAX (21 years) vs JVMCX (15 years). JVMCX (1.86) is less costly to investors than ACLAX (1.22). ACLAX (50.00) and JVMCX (49.00) have comparable annual turnover. JVMCX has a lower initial minimum investment than ACLAX: JVMCX (1000) vs ACLAX (2500). JVMCX annual gain was more profitable for investors over the last year : 5.42 vs. ACLAX (2.58). JVMCX return over 5 years is better than : -1.33 vs. ACLAX (-16.06).
ACLAXJVMCXACLAX / JVMCX
Total Expense Ratio1.221.8566%
Annual Report Gross Expense Ratio1.221.8666%
Fund Existence21 years15 years-
Gain YTD7.1065.747124%
Front Load6%N/A-
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets5.58B22.5B25%
Annual Yield % from dividends1.110.00-
Returns for 1 year2.585.4248%
Returns for 3 years7.8414.9852%
Returns for 5 years-16.06-1.331,204%
Returns for 10 years11.5439.2429%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLGL74.183.78
+5.36%
Sol-Gel Technologies Ltd
ROCK38.030.29
+0.78%
Gibraltar Industries
SPG203.530.83
+0.41%
Simon Property Group
KVYO16.95-1.41
-7.68%
Klaviyo
SNSE15.95-3.84
-19.40%
Sensei Biotherapeutics Inc